An interventional study of patient navigation and self-collection in Diabetes, Cervical Cancer (Early Detection) and Obesity & Overweight, sponsored by University of Florida. Recruiting at 1 site in United States. Open to female participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by University of Florida · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus by University of Florida — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · University of Florida.
Among the 15 studies in Diabetes Mellitus by University of Florida, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 14th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →3 of the 15 studies in Diabetes Mellitus by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 20–75
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 25 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 83 across the 12 interventional studies, 18 across the 3 observational. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
1 of the studies in Diabetes Mellitus by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05561595University of FloridaTransdiagnostic Intervention to Reduce Internalized Health-Related Stigma | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus by University of Florida, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer.
We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer. We will use the six steps of the Intervention Mapping approach to guide the process of testing the intervention. This project aligns with the current efforts at the University of Florida Health Cancer Institute (UFHCI) and UF Health Internal Medicine to improve cervical cancer screening rates among under-screened women. We will partner with these efforts to test the PINPOINT intervention. Project CONTINUITY (Connecting You to Care in the Community) at UFHCI, Office of Community Outreach and Engagement (COE), is working to increase adherence to cervical screening and follow-up by; (1) providing personalized approaches to improve adherence through the combined use of patient choice for the initial screening method, community clinical navigators (CCN) and community health workers (CHWs), customized messages and support for patient portal access for test results, and (2) implementing strategies to address non-medical drivers that may influence an individual's ability to adhere to the screening, with an initial focus on removing transportation barriers through the use of a mobile outreach clinic (MOC).
Currently, a patient navigator supervised by Dr. Dianne Goede identifies patients who have an upcoming office visit and are due for cervical cancer screening at UF Health Internal Medicine. The patient navigator outreaches the patient, reminds them of their overdue status for cervical cancer screening and the importance of cervical cancer screening, and inquires if they are agreeable to complete screening at the scheduled office visit. We will reach out to patients who remain unscreened for cervical cancer 2 months after their scheduled visit with UF Health Internal Medicine. We will obtain a list of patients from the UF Health Consent2Share database. Patients who agree to participate in our study will be randomized to either receive the PINPOINT intervention (self-collection test with patient navigation) or standard of care (reminder to screen from UF Health Internal Medicine). We will use the sealed envelope randomization method to assign participants to either treatment or control groups right after intake.
We will pilot the PINPOINT intervention at UF Internal Medicine clinics and use Proctor's Framework for Implementation Outcomes to evaluate the intervention. Changes will be made to the intervention protocol and tested in a future randomized trial with a larger sample. Hypothesis: PINPOINT will meet the needs of women living with socioeconomic challenges, T2D, and obesity, and will align with the clinical workflow. PINPOINT will be appropriate, feasible and acceptable.27 Outcome: The PINPOINT intervention will have positive outcomes in terms of feasibility and acceptability among patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following eligibility criteria will be used to determine inclusion into the study:
Exclusion Criteria:
PINPOINT intervention arm will entail assigning patients to a patient navigator to assist them with screening reminders and address any barriers they have to screening, education on cervical cancer screening, and patients will also be offered the opportunity to self-collect their sample for cervical cancer screening.
Behavioral: patient navigation and self-collection
No intervention arm, patients will receive reminders for screening according to current clinical practice
Patients will receive a combination of patient navigation, education, and cervical cancer self-collection sampling as part of the intervention to support cervical cancer screening.
Also known as: self-collection, self-sampling, patient navigation
Cervical cancer screening
receiving cervical cancer screening either via self-collection, pap smear, or hpv testing
Time frame: within 6 months
Acceptability
How agreeable or satisfactory participants find the intervention or implementation strategy. Questions include, HPV Self-Collection meets my approval, HPV Self-Collection is appealing to me, I like HPV Self-Collection, and I welcome HPV Self-Collection. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).
Time frame: from enrollment until they complete screening or at the end of the trial at 6 months
Appropriateness
The perceived fit or compatibility of the intervention for a specific setting, provider, or consumer, or to address a problem. Questions include, HPV Self-Collection seems fitting, HPV Self-Collection seems suitable, HPV Self-Collection seems applicable., and HPV Self-Collection seems like a good match. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).
Time frame: from enrollment until they complete screening or at the end of the trial at 6 months
Feasibility measure
\- The extent to which an intervention can be successfully used in a given setting. Questions include, HPV Self-Collection seems implementable, HPV Self-Collection seems possible, HPV Self-Collection seems doable, and HPV Self-Collection seems easy to use. Participants will fill a 4 point likert scale for each, (completely disagree, disagree, neither agree not disagree, agree, completely agree).
Time frame: from enrollment until they complete screening or at the end of the trial at 6 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Deidentified data will be available after the results of the study are published.
Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.